KRAS G12C mutation: from undruggable target to potentially agnostic biomarker

Transl Lung Cancer Res. 2023 Jun 30;12(6):1147-1151. doi: 10.21037/tlcr-23-174. Epub 2023 May 23.

Author

Badi El Osta^{1

2

3}

Affiliations

¹ Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
² Atlanta VA Medical Center, Decatur, GA, USA.
³ Winship Cancer Institute of Emory University, Atlanta, GA, USA.

No abstract available

Keywords: Kristen rat sarcoma (KRAS); Non-small cell lung cancers (NSCLC); precision oncology; targeted therapy.

Publication types

Editorial
Comment